CEO David Kalergis from Diffusion Pharmaceuticals (NASDAQ:DFFN) tells Proactive Investors the company is using their technology to move more oxygen into oxygen-deprived tissues for cancer cells, as oxygen deprived cancer cells are three times more resistant to chemotherapy and radiation then normally oxygenated cancer cells.
Kalergis says they have opened a phase 3 study for newly diagnosed, inoperable brain cancer patients, in which they saw a fourfold increase in two year survival in their phase 2 study.
Meet Scancell Holdings Plc, Advanced Blast & Ballistic Systems Ltd and TokenCommunities Plc at our event, London, 08 March 2018.Register here >>